Skip to main content
Merck KGaA (MKGAF)
OTCMKTS · Delayed Price · Currency is USD
140.50
-0.55 (-0.39%)
May 2, 2025, 3:58 PM EDT

Revenue by Product

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Life Science
8.92B
Log In
Log In
Log In
Log In
Life Science Growth
-3.93%
Log In
Log In
Log In
Log In
Healthcare
8.45B
Log In
Log In
Log In
Log In
Healthcare Growth
4.98%
Log In
Log In
Log In
Log In
Electronics
3.79B
Log In
Log In
Log In
Log In
Electronics Growth
3.45%
Log In
Log In
Log In
Log In
Oncology
2.01B
Log In
Log In
Log In
Log In
Oncology Growth
10.47%
Log In
Log In
Log In
Log In
Neurology & Immunology
1.69B
Log In
Log In
Log In
Log In
Neurology & Immunology Growth
1.39%
Log In
Log In
Log In
Log In
Fertility
1.53B
Log In
Log In
Log In
Log In
Fertility Growth
-1.25%
Log In
Log In
Log In
Log In
Display Solutions
748.00M
Log In
Log In
Log In
Log In
Display Solutions Growth
-2.82%
Log In
Log In
Log In
Log In
Surface Solutions
406.50M
Log In
Log In
Log In
Log In
Surface Solutions Growth
-1.07%
Log In
Log In
Log In
Log In
Semiconductor Solutions
2.63B
Log In
Log In
Log In
Log In
Semiconductor Solutions Growth
6.14%
Log In
Log In
Log In
Log In
Cardiovascular, Metabolism and Endocrinology
2.95B
Log In
Log In
Log In
Log In
Cardiovascular, Metabolism and Endocrinology Growth
5.82%
Log In
Log In
Log In
Log In
Other Healthcare
280.50M
Log In
Log In
Log In
Log In
Other Healthcare Growth
19.20%
Log In
Log In
Log In
Log In
Process Solutions
3.52B
Log In
Log In
Log In
Log In
Process Solutions Growth
-6.86%
Log In
Log In
Log In
Log In
Life Science Services
722.10M
Log In
Log In
Log In
Log In
Life Science Services Growth
-8.85%
Log In
Log In
Log In
Log In
Science & Lab Solutions
4.67B
Log In
Log In
Log In
Log In
Science & Lab Solutions Growth
-0.74%
Log In
Log In
Log In
Log In

EBITDA by Product

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Life Science EBITDA
2.59B
Log In
Log In
Log In
Log In
Life Science EBITDA Growth
-8.17%
Log In
Log In
Log In
Log In
Healthcare EBITDA
2.99B
Log In
Log In
Log In
Log In
Healthcare EBITDA Growth
17.76%
Log In
Log In
Log In
Log In
Electronics EBITDA
969.60M
Log In
Log In
Log In
Log In
Electronics EBITDA Growth
6.21%
Log In
Log In
Log In
Log In
Corporate/Others EBITDA
-481.80M
Log In
Log In
Log In
Log In
Corporate/Others EBITDA Growth
21.46%
Log In
Log In
Log In
Log In

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Europe
6.17B
Log In
Log In
Log In
Log In
Europe Growth
2.21%
Log In
Log In
Log In
Log In
North America
5.71B
Log In
Log In
Log In
Log In
North America Growth
-4.06%
Log In
Log In
Log In
Log In
Asia Pacific
7.02B
Log In
Log In
Log In
Log In
Asia Pacific Growth
1.18%
Log In
Log In
Log In
Log In
Latin America
1.48B
Log In
Log In
Log In
Log In
Latin America Growth
10.93%
Log In
Log In
Log In
Log In
Middle East & Africa
781.20M
Log In
Log In
Log In
Log In
Middle East & Africa Growth
5.98%
Log In
Log In
Log In
Log In